ClinicalTrials.gg
TerminatedNCT03995173TMS_AUD+mTBIUpdated Oct 30, 2026Results posted

Pilot rTMS for AUD+mTBI

A Phase 2 interventional study of repetitive transcranial magnetic stimulation in Alcohol Use Disorder, Mild Traumatic Brain Injury and Post-traumatic Stress Disorder, sponsored by VA Office of Research and Development. Terminated at 1 site in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
COVID and funding
Updated Oct 30, 2026Now TerminatedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Alcoholism by VA Office of Research and Development — 7 open to participants now, 9 under way, 2 of them phase 3. Alcoholism · VA Office of Research and Development.

Enrollment
41st of 42
2 · median 96
Started
2019
with 3 others
Phase 2
6 of 47
1 open now
Registered
31st of 47
by date

Among the 47 studies in Alcoholism by VA Office of Research and Development, this one is the 41st largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2019, is one of 6 in phase 2, and was the 31st registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

7 of the 47 studies in Alcoholism by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Alcoholism by VA Office of Research and Development, or all of them as a file.
02

Study summary

This is a pilot randomized controlled trial (RCT) for Veteran participants with alcohol use disorder co-occurring with mild traumatic brain injury and/or post-traumatic stress disorder. The treatment intervention is repetitive Transcranial Magnetic Stimulation (rTMS) and the goal is to reduce alcohol craving with this treatment. The study will enroll 20 Veteran participants. Half of these participants will receive real rTMS and half of the participants will receive placebo rTMS. rTMS treatment will be provided over 10 sessions that will occur once every weekday for 2 weeks. Veteran participants will then complete follow-up phone calls to further evaluate alcohol craving and other symptoms.

Read the detailed description

Mild traumatic brain injury (mTBI), post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) are high priority disorders for the Department of Veterans Affairs (VA), in part, because these disorders rarely occur in isolation. The co-occurrence compounds brain impairment and negatively impacts symptom presentation and rehabilitation effectiveness. Veterans with co-occurring AUD, mTBI and/or PTSD have few effective treatment options. Thus, treatment development for these Veterans is of great need. The aim of this protocol is to examine safety, feasibility, and the behavioral and neural effects of an repetitive transcranial magnetic stimulation (rTMS) intervention for Veterans with AUD and co-occurring mTBI and/or PTSD. Behavioral and neural effects of rTMS will be examined after the first rTMS session and after the last rTMS session. The investigators hypothesize that the rTMS intervention will be 1) safe, 2) feasible and 3) efficacious. Specifically, the investigators hypothesize that there will be no adverse events related to the rTMS intervention. The investigators hypothesize that all participants enrolled will successfully complete all rTMS sessions. The investigators hypothesize that participants treated with active rTMS, relative to placebo rTMS, will have reduced alcohol craving severity levels. Finally, the investigators hypothesize that participants treated with active rTMS relative to placebo rTMS will have reduced brain activation in response to alcohol cues and improved functional connectivity after the last rTMS session. This is a prospective, pilot, double-blind randomized controlled trial of the intervention rTMS. There will be 2 groups of Veterans with AUD and co-occurring mTBI and/or PTSD those given 1) active rTMS and those given 2) placebo rTMS. Targeted enrollment for this study is 20 Veterans: n=10 active rTMS and n=10 placebo rTMS. Participants will be screened for safety and evaluated on mental health-related behavioral measures. Eligible participants will be randomized to receive active or placebo rTMS. Participants will then complete motor thresholding (MT) to determine rTMS intensity. Participants will then complete 10 sessions of rTMS. These sessions will be completed once daily on week days over two weeks. TMS pulses will be applied to the left DLPFC at 10Hz rate, 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. After the 10th rTMS session, participants will complete an MRI which will last approximately 1hour. A sub-sample of participants will complete an MRI immediately after the first rTMS session. Participants will also repeat the mental health behavioral measures after the last rTMS session. Participants will complete follow-up phone interviews to assess for alcohol craving, mTBI symptoms and PTSD symptoms at one day, one week and one month post-rTMS. Completion of this study is an essential first step towards treatment development for Veterans with co-occurring AUD, mTBI and/or PTSD.

03

Conditions studied

  • Alcohol Use Disorder
  • Mild Traumatic Brain Injury
  • Post-traumatic Stress Disorder

Keywords

  • alcoholism
  • brain concussion
  • post-traumatic stress disorder
04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English Speaking
  • Veterans
  • Ages 22 through 65
  • Meeting AUDIT-C criteria for AUD (4 for men and 3 for women)
  • Pass MRI screening using the Center for Translational Imaging (CTI) Safety Form.
  • Clinical Institute of Withdrawal Assessment in Alcohol Withdrawal (CIWA-Ar) scores of 10

Exclusion criteria

Exclusion Criteria:

  • History of moderate to severe TBI
  • Documented and verified history of psychotic spectrum disorders (i.e., schizophrenia, bipolar)
  • Receipt of anti-epileptic medications to control active seizures or evidence of documented seizure within past six months
  • Receipt of tricyclic anti-depressants, antipsychotic agents, or other drugs that lower the seizure threshold
  • Current use of:

    • opiates
    • cocaine
    • amphetamines
    • barbiturates
    • benzodiazepine
    • marijuana/cannabis dependence as determined by the SCID-IV
  • Currently prescribed any anti-craving/addiction medications, i.e.:

    • naltrexone
    • varenicline
    • bupropion
    • disulfiram
    • acamprosate
  • Meet questionable validity or malingering criteria on the Minnesota Multiphasic Personality Inventory-2-RF (MMPI-2-RF; F: T score 107; F(p): T score 85; TRIN: T score 80; VRIN: T score 80) or the Letter Memory Test (LMT; total score 92%), as determined in IRB#13-077
  • Pregnant or nursing
  • Have congestive heart failure
  • Have cardiac pacemaker or defibrillator, or:

    • cochlear implant
    • nerve stimulator
    • intracranial metal clips
    • implanted medical pump
    • increased intracranial pressure
  • History of:

    • surgery on blood vessels in brain and/or valves of the heart
    • brain hemorrhage
    • neurovascular conditions
    • neurodegenerative disorders
    • claustrophobia
    • metal in eye/face
    • shrapnel/bullet remnants in brain
  • Actively suicidal as evidenced by plan to harm or recent attempt communicated on the BDI-II or electronic medical record within the past 6 months
  • History of mild TBI within the last 3 months
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Active comparator
    active

    active rTMS

    Device: repetitive transcranial magnetic stimulation

  • Placebo comparator
    placebo

    placebo rTMS

    Device: repetitive transcranial magnetic stimulation

Interventions

  • Devicerepetitive transcranial magnetic stimulation

    rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.

    Also known as: transcranial magnetic stimulation

06

What researchers measure

Primary outcomes

  1. Total Adverse Event Frequency

    An adverse event log will be kept for each participant and each rTMS treatment session. After each treatment these events will be recorded and the total frequency of events will be used as the outcome after all 10 rTMS sessions over the course of the 2 week treatment have been completed.

    Time frame: immediately after last/10th rTMS session - up to 2 weeks

  2. Total rTMS Sessions Completed

    Total number of rTMS treatment sessions completed out of 10 sessions. After all 10 rTMS sessions over the course of the 2 week treatment this cumulative total number of sessions complete can be computed.

    Time frame: after the 10th and last rTMS treatment session - up to 2 weeks

Secondary outcomes

  1. Penn Alcohol Craving Scale

    Penn Alcohol Craving Scale. Self report measure of 5 questions rated on a scale of 0-6, with higher scores indicating more severe craving. Minimum possible total score is 0 and maximum possible total score is 30, with higher scores indicating more severe craving.

    Time frame: baseline (pre-treatment), immediately after last/10th TMS session, approximately 2 weeks later

07

Results

Posted Oct 30, 2026
Limitations and caveats
After only one participant was randomized, the study was stopped due to COVID-19 pandemic, and was never resumed due to ending of grant funding. The only patient who was randomized did complete all research procedures but they were randomized to the placebo group.

Participant flow

Veterans that previously participated in previous IRB-approved studies on AUD+mTBI and who consented to be enrolled in a IRB-approved TBI data repository will be invited to participate. Veterans were mailed invitational letters with an opt-out card, and if an opt-out card wasn't received, then a follow-up phone call was made for recruitment and screening. No more than 2 voice messages and 3 phone calls will be made.

Participant flow — Overall Study
MilestoneActivePlacebo
Started01
Completed01
Not completed00

Outcome measures

PrimaryTotal Adverse Event Frequency

An adverse event log will be kept for each participant and each rTMS treatment session. After each treatment these events will be recorded and the total frequency of events will be used as the outcome after all 10 rTMS sessions over the course of the 2 week treatment have been completed.

Time frame:
immediately after last/10th rTMS session - up to 2 weeks
Reported as:
Number · Count of Adverse Events
Total Adverse Event Frequency
Count of Adverse EventsActivePlacebo
Total Adverse Event Frequency—1
PrimaryTotal rTMS Sessions Completed

Total number of rTMS treatment sessions completed out of 10 sessions. After all 10 rTMS sessions over the course of the 2 week treatment this cumulative total number of sessions complete can be computed.

Time frame:
after the 10th and last rTMS treatment session - up to 2 weeks
Reported as:
Number · Number of sessions completed
Total rTMS Sessions Completed
Number of sessions completedActivePlacebo
Total rTMS Sessions Completed—10
SecondaryPenn Alcohol Craving Scale

Penn Alcohol Craving Scale. Self report measure of 5 questions rated on a scale of 0-6, with higher scores indicating more severe craving. Minimum possible total score is 0 and maximum possible total score is 30, with higher scores indicating more severe craving.

Time frame:
baseline (pre-treatment), immediately after last/10th TMS session, approximately 2 weeks later
Reported as:
Number · score on a scale
Penn Alcohol Craving Scale
score on a scaleActivePlacebo
baseline, pre-treatment—3
immediately after last/10th TMS session, approximately 2 weeks later—1

Adverse events

Collected over from beginning of TMS treatment until after the last rTMS treatment, up to 2 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active———
Placebo0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventActivePlacebo
eye blinking and transient blurriness and seeing black dots, likely due to dry eyesEye disorders—1/1

Baseline characteristics

Two participants were enrolled, one was randomized and had baseline data collected.

Age, Categorical
Age, Categorical(Participants)ActivePlaceboTotal
<=18 years000
Between 18 and 65 years011
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)ActivePlaceboTotal
Female000
Male011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ActivePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)ActivePlaceboTotal
United States—11
08

Study locations

1 site
  • Edward Hines Jr. VA Hospital, Hines, IL
    Hines, Illinois 60141-3030, United States
09

References and documents

Publications

  • Herrold AA, Kletzel SL, Harton BC, Chambers RA, Jordan N, Pape TL. Transcranial magnetic stimulation: potential treatment for co-occurring alcohol, traumatic brain injury and posttraumatic stress disorders. Neural Regen Res. 2014 Oct 1;9(19):1712-30. doi: 10.4103/1673-5374.143408. PubMed 25422632 ↗
  • Herrold AA, Siddiqi SH, Livengood SL, Bender Pape TL, Higgins JP, Adamson MM, Leung A, Raij T. Customizing TMS Applications in Traumatic Brain Injury Using Neuroimaging. J Head Trauma Rehabil. 2020 Nov-Dec;35(6):401-411. doi: 10.1097/HTR.0000000000000627. PubMed 33165153 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2019 to primary completion in Mar 2020, 12 months.

Results were first posted in Oct 2026, 6 years 6 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Mar 2026 → Mar 2020 and completion Mar 2026 → Mar 2020.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2019
First posted
Jun 21, 2019
StartActual
Mar 21, 2019
Primary completionActual
Mar 31, 2020was Mar 2026
CompletionActual
Mar 31, 2020was Mar 2026
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated COVID and funding
changed Oct 30, 2026
Results
Results posted
posted Oct 30, 2026
Primary completion
Mar 31, 2026→Mar 31, 2020 (actual)
Oct 30, 2026
Study completion
Mar 31, 2026→Mar 31, 2020 (actual)
Oct 30, 2026
Enrollment
1→2
Oct 30, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedPenn Alcohol Craving Scale ChangeTime frame: baseline, immediately after last/10th rTMS session, and 1 day, 1 week, and 1 month follow-up
Oct 30, 2026
Documents
Publications
Results publication added: Herrold AA, Siddiqi SH, Livengood SL, Bender Pape TL, Higgins JP, Adamson MM, Leung A, Raij T. Customizing TMS Applications in Traumatic Brain Injury Using Neu… PubMed 33165153 ↗
Oct 30, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedPenn Alcohol Craving ScaleTime frame: baseline (pre-treatment), immediately after last/10th TMS session, approximately 2 weeks later
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Terminated
    Why stopped COVID and funding
    Results posted
    Publications Results publication added: Herrold AA, Siddiqi SH, Livengood SL, Bender Pape TL, Higgins JP, Adamson MM, Leung A, Raij T. Customizing TMS Applications in Traumatic Brain Injury Using Neu… PubMed 33165153 ↗
    Primary completion Mar 31, 2026→Mar 31, 2020 (now actual)
    Study completion Mar 31, 2026→Mar 31, 2020 (now actual)
    Enrollment 1→2
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedPenn Alcohol Craving Scale ChangeTime frame: baseline, immediately after last/10th rTMS session, and 1 day, 1 week, and 1 month follow-up
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedPenn Alcohol Craving ScaleTime frame: baseline (pre-treatment), immediately after last/10th TMS session, approximately 2 weeks later
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03995173
Responsible party
Sponsor
First posted
Jun 21, 2019
Start date
Mar 21, 2019
Primary completion
Mar 31, 2020
Completion
Mar 31, 2020
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Amy A Herrold, PhD BA
principal investigator · Edward Hines Jr. VA Hospital, Hines, IL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion